Artery Research

<Previous Article In Issue
Next Article In Issue>
Volume 25, Issue 1-2, June 2019, Pages 19 - 25

Treatment of White Coat HYpertension in the Very Elderly Trial (HYVET 2) - Feasibility of a Randomized Controlled Trial (Study Protocol)

Authors
Michael Okorie1, 2, *, Khalid Ali1, 2, Stephen Bremner3, Nigel Beckett4, Stephen Jackson5, Richard Quirk6, Colin McAlister7, Nicky Perry2, John Potter8, Christopher Bulpitt9, Chakravarthi Rajkumar1, 2
1Department of Medicine, Brighton and Sussex Medical School, Brighton, UK
2Brighton and Sussex University Hospitals NHS Trust, Brighton, UK
3Department of Primary Care and Public Health, Brighton and Sussex Medical School, Brighton, UK
4Department of Ageing and Health, Guy’s and St Thomas’ NHS Foundation Trust, London, UK
5Department of Clinical Gerontology, King’s College Hospital, London, UK
6Sussex Community NHS Foundation Trust, Brighton, UK
7University of Sussex, Brighton, UK
8Norwich Medical School, University of East Anglia, Norwich, UK
9Faculty of Medicine, Imperial College London, UK
*Corresponding author. Email: M.Okorie@bsms.ac.uk
Corresponding Author
Michael Okorie
Received 28 October 2019, Accepted 1 November 2019, Available Online 18 November 2019.
DOI
10.2991/artres.k.191106.001How to use a DOI?
Keywords
White coat hypertension; treatment; feasibility study; very elderly
Abstract

The results of HYpertension in the Very Elderly Trial (HYVET) were crucial in providing evidence of benefit of the treatment of hypertension in those 80 years or older. Following a subsequent sub study analysis of the HYVET data there is a suggestion that 50% of patients in the main study had White Coat Hypertension (WCH), defined as clinic BP readings >140/90 mmHg and ambulatory BP readings <135/85 mmHg. Currently, definitive evidence in support of treatment for such individuals is not available. HYVET 2 has been designed in order to assess the feasibility of conducting a randomized controlled trial which might determine whether the treatment of WCH in the very elderly is clinically beneficial. One hundred participants aged ≥75 years diagnosed with WCH will be recruited from General Practices (GPs) in UK. Randomization will be 1:1 to a treatment arm (indapamide and perindopril) and control arm (no treatment) and follow up will be for 52 weeks. HYVET 2 will report on feasibility outcomes including participant recruitment, adherence and withdrawal rates, willingness of GPs to recruit and randomize patients and the frequency of a composite of cardiovascular events. Simple descriptive statistics will be presented.

Copyright
© 2019 Association for Research into Arterial Structure and Physiology. Publishing services by Atlantis Press International B.V.
Open Access
This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).

Download article (PDF)
View full text (HTML)

<Previous Article In Issue
Next Article In Issue>
Journal
Artery Research
Volume-Issue
25 - 1-2
Pages
19 - 25
Publication Date
2019/11/18
ISSN (Online)
1876-4401
ISSN (Print)
1872-9312
DOI
10.2991/artres.k.191106.001How to use a DOI?
Copyright
© 2019 Association for Research into Arterial Structure and Physiology. Publishing services by Atlantis Press International B.V.
Open Access
This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).

Cite this article

risenwbib
TY  - JOUR
AU  - Michael Okorie
AU  - Khalid Ali
AU  - Stephen Bremner
AU  - Nigel Beckett
AU  - Stephen Jackson
AU  - Richard Quirk
AU  - Colin McAlister
AU  - Nicky Perry
AU  - John Potter
AU  - Christopher Bulpitt
AU  - Chakravarthi Rajkumar
PY  - 2019
DA  - 2019/11/18
TI  - Treatment of White Coat HYpertension in the Very Elderly Trial (HYVET 2) - Feasibility of a Randomized Controlled Trial (Study Protocol)
JO  - Artery Research
SP  - 19
EP  - 25
VL  - 25
IS  - 1-2
SN  - 1876-4401
UR  - https://doi.org/10.2991/artres.k.191106.001
DO  - 10.2991/artres.k.191106.001
ID  - Okorie2019
ER  -